<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Seven patients with <z:hpo ids='HP_0004808'>acute myeloblastic leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) occurring on <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) were consolidated while in complete remission (CR) by autologous bone marrow transplantation (ABMT) with a marrow purged in vitro by mafosfamide </plain></SENT>
<SENT sid="1" pm="."><plain>The median age of population was 44 years (range 39-55) </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> FAB diagnosis was established before progression to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in five patients: refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excess of blast (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) in three patients, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t) in one patient, and <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) in one patient </plain></SENT>
<SENT sid="3" pm="."><plain>In the remaining two patients, the diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (as a <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">secondary malignancy</z:e> in one) was made retrospectively at time of overt <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Three out the seven patients had karyotypic abnormalities </plain></SENT>
<SENT sid="5" pm="."><plain>The median interval between the obtention of CR and ABMT was 7 months (range 6-18) </plain></SENT>
<SENT sid="6" pm="."><plain>One patient died from transplant related toxicity </plain></SENT>
<SENT sid="7" pm="."><plain>Engraftment occurred at a median of 41 days (range 27-60), for white blood cells (&gt; 10(9)/l) and 120 days (range 60-180) for platelets (&gt; 50 x 10(9)/l) </plain></SENT>
<SENT sid="8" pm="."><plain>Four patients relapsed at 2.5, 6.8, and 25 months post-ABMT </plain></SENT>
<SENT sid="9" pm="."><plain>Two patients are alive and well at 10 and 28 months, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>ABMT with marrow purged by mafosfamide is feasible in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> following <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with a prospect of cure </plain></SENT>
<SENT sid="11" pm="."><plain>However, further studies are needed to assess the real value of this approach </plain></SENT>
</text></document>